cbdMD, Inc.
YCBD-PA
New York Stock Exchange Arca1.35
USD
+0.21
- -
CIK
0001644903
ISIN
US12482W2008
CUSIP
12482W200
Return %
Stock
S&P500
1Y
83.66
26.53
3Y
-67.70
76.60
5Y
-84.28
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- T. Ronan Kennedy
- Full Time Employees
- 42
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 8845 Red Oak Boulevard Charlotte NC United States of America 28217
- IPO Date
- Oct 21, 2019
- CIK
- 0001644903
- Website
- cbdmd.com
- Similar Companies
- Business
- cbdMD, Inc. (NYSE American: YCBD) produces and distributes premium cannabidiol (CBD) and hemp-derived products primarily in the United States through consumer brands including cbdMD, Paw CBD, hempMD, cbdMD Botanicals, and ATRx; its cbdMD brand offers CBD tinctures, gummies, topicals, capsules, drink mixes, ready-to-drink cans, bath bombs, sleep aids, focus aids, and calming aids, while Paw CBD provides veterinarian-formulated pet products such as tinctures, chews, and topicals, hempMD supplies hemp-derived solutions, and ATRx features a nootropic mushroom line. The company, founded in 2015 and headquartered in Charlotte, North Carolina, distributes its offerings via e-commerce websites, third-party platforms, wholesalers, distributors, marketing partners, and brick-and-mortar retailers including convenience stores and specialty shops, targeting wellness-focused consumers, pet owners, and individuals seeking relief from stress, sleep issues, pain, and anxiety. cbdMD operates in the health and wellness sector with a focus on THC-free and Farm Act compliant Delta 9 products, NSF Certified for Sport options, full spectrum variants, and GMP-certified manufacturing using USA-grown hemp, supported by independent lab testing and a 60-day guarantee. Recent developments include the expansion of its Herbal Oasis THC-infused social seltzer brand through a key distribution partnership with Bevtalk in most of Florida targeting convenience stores, independent retailers, and beverage accounts as of October 2025, alongside wholesale net sales growth of 22% in Q2 2025 driven by new distribution partnerships and the Herbal Oasis line; the company pursues further Southeast rollout, cross-selling synergies between CBD/Delta products and Oasis, financial restructuring for profitability, and strategic opportunities in partnerships, acquisitions, and category expansions to enhance revenue and shareholder value. Formerly known as Level Brands, Inc., cbdMD changed its name in May 2019 and maintains a wholly-owned subsidiary, cbdMD Therapeutics LLC, for science and R&D investments in therapeutic applications.